Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 2001 Nov;54(11):866–870. doi: 10.1136/jcp.54.11.866

p21waf correlates with DNA replication but not with prognosis in invasive breast cancer

U Gohring 1, A Bersch 1, M Becker 1, W Neuhaus 1, T Schondorf 1
PMCID: PMC1731310  PMID: 11684722

Abstract

Background/Aims—p21waf plays a central role both in the regulation of the cell cycle and in DNA replication. Accordingly, p21waf is a putative tumour suppressor. The role of p21waf expression in breast cancer is still unclear, particularly with respect to the clinical situation. Therefore, this retrospective study was designed to investigate the value of immunohistochemically detected p21waf expression in invasive breast cancer.

Methods—Cellular expression of p21waf was assessed in 307 breast cancer tissues by immunohistochemistry using the monoclonal antibody, clone 4D10. The data were correlated to established and functional factors of prognosis (age, menopausal status, tumour size, nodal status, tumour grade, receptor status, proliferating cell nuclear antigen (PCNA) expression, Her-2/neu expression, and p53 expression), and to clinical follow up (median observation time, 82 months).

Results—Ninety nine of 307 (32.2%) tumour tissues were considered p21waf positive (nuclear staining). In the entire study group, p21waf expression correlated only with increased PCNA expression (χ2 test: p = 0.029), and with none of the other investigated markers. In node negative patients (n = 134), p21waf expression correlated with increased tumour size and increased PCNA expression, whereas the node positive subgroup (n = 161) showed no correlation with these parameters (lymphonodectomy was done in 295 women). With respect to clinical outcome, p21waf expression showed a definite favourable trend in both subgroups (N0: p21waf negative, 23 of 87; p21waf positive, nine of 43. N+: p21waf negative, 63 of 107; p21waf positive, 23 of 52), but this observation was not significant (p > 0.05). Multivariate analysis for disease free survival as indicated by Cox regression analysis included all factors investigated. The most striking parameters were nodal status (relative risk (RR), 1.74; p = 0.00001), receptor status (RR, 0.59; p = 0.0085), tumour size (RR, 1.42; p = 0.02), and Her2/neu expression (RR, 1.56; p = 0.033). p21waf expression was not significant in the multivariate analysis (p > 0.05).

Conclusions—p21waf expression is an independent factor but fails to be of prognostic or predictive value in multivariate analysis. These data confirm the hypothesis of a p53 independent p21waf induction and suggest a functional role in the inhibition of PCNA mediated DNA replication.

Key Words: p21waf • proliferating cell nuclear antigen • p53 • breast cancer • immunohistochemistry • prognosis

Full Text

The Full Text of this article is available as a PDF (163.7 KB).

graphic file with name 00197.f1.jpg

Open in a new tab

Figure 1 Positive p21waf staining in the nuclei of tumour cells in an infiltrating ductal breast cancer (immunoreactive score, 6).

graphic file with name 00197.f2.jpg

Open in a new tab

Figure 2 Kaplan-Meier curves for disease free survival (event = relapse) for (A) node negative (n = 130) and (B) node positive (n = 159) subgroups. Only trends could be observed (log rank test: p > 0.05).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbareschi M., Pelosio P., Caffo O., Buttitta F., Pellegrini S., Barbazza R., Dalla Palma P., Bevilacqua G., Marchetti A. Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. Int J Cancer. 1997 Apr 22;74(2):171–174. doi: 10.1002/(sici)1097-0215(19970422)74:2<171::aid-ijc5>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]
  2. Bukholm I. K., Nesland J. M., Kåresen R., Jacobsen U., Børresen-Dale A. L. Interaction between bcl-2 and p21 (WAF1/CIP1) in breast carcinomas with wild-type p53. Int J Cancer. 1997 Sep 26;73(1):38–41. doi: 10.1002/(sici)1097-0215(19970926)73:1<38::aid-ijc7>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  3. Caffo O., Doglioni C., Veronese S., Bonzanini M., Marchetti A., Buttitta F., Fina P., Leek R., Morelli L., Palma P. D. Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin Cancer Res. 1996 Sep;2(9):1591–1599. [PubMed] [Google Scholar]
  4. Chen U., Chen S., Saha P., Dutta A. p21Cip1/Waf1 disrupts the recruitment of human Fen1 by proliferating-cell nuclear antigen into the DNA replication complex. Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11597–11602. doi: 10.1073/pnas.93.21.11597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chen Y. Q., Cipriano S. C., Arenkiel J. M., Miller F. R. Tumor suppression by p21WAF1. Cancer Res. 1995 Oct 15;55(20):4536–4539. [PubMed] [Google Scholar]
  6. Elledge R. M., Allred D. C. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat. 1998;52(1-3):79–98. doi: 10.1023/a:1006163101948. [DOI] [PubMed] [Google Scholar]
  7. Fernández P. L., Jares P., Rey M. J., Campo E., Cardesa A. Cell cycle regulators and their abnormalities in breast cancer. Mol Pathol. 1998 Dec;51(6):305–309. doi: 10.1136/mp.51.6.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Flores-Rozas H., Kelman Z., Dean F. B., Pan Z. Q., Harper J. W., Elledge S. J., O'Donnell M., Hurwitz J. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8655–8659. doi: 10.1073/pnas.91.18.8655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gorospe M., Liu Y., Xu Q., Chrest F. J., Holbrook N. J. Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2. Mol Cell Biol. 1996 Mar;16(3):762–770. doi: 10.1128/mcb.16.3.762. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Göhring U. J., Scharl A., Heckel C., Ahr A., Crombach G. P53 protein in 204 patients with primary breast carcinoma--immunohistochemical detection and clinical value as a prognostic factor. Arch Gynecol Obstet. 1995;256(3):139–146. doi: 10.1007/BF01314642. [DOI] [PubMed] [Google Scholar]
  11. Jacks T., Weinberg R. A. The expanding role of cell cycle regulators. Science. 1998 May 15;280(5366):1035–1036. doi: 10.1126/science.280.5366.1035. [DOI] [PubMed] [Google Scholar]
  12. Jiang M., Shao Z. M., Wu J., Lu J. S., Yu L. M., Yuan J. D., Han Q. X., Shen Z. Z., Fontana J. A. p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int J Cancer. 1997 Oct 21;74(5):529–534. doi: 10.1002/(sici)1097-0215(19971021)74:5<529::aid-ijc9>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  13. Jones J. M., Cui X. S., Medina D., Donehower L. A. Heterozygosity of p21WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model. Cell Growth Differ. 1999 Apr;10(4):213–222. [PubMed] [Google Scholar]
  14. Lallemand F., Courilleau D., Buquet-Fagot C., Atfi A., Montagne M. N., Mester J. Sodium butyrate induces G2 arrest in the human breast cancer cells MDA-MB-231 and renders them competent for DNA rereplication. Exp Cell Res. 1999 Mar 15;247(2):432–440. doi: 10.1006/excr.1998.4370. [DOI] [PubMed] [Google Scholar]
  15. Li R., Waga S., Hannon G. J., Beach D., Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature. 1994 Oct 6;371(6497):534–537. doi: 10.1038/371534a0. [DOI] [PubMed] [Google Scholar]
  16. Mathoulin-Portier M. P., Viens P., Cowen D., Bertucci F., Houvenaeghel G., Geneix J., Puig B., Bardou V. J., Jacquemier J. Prognostic value of simultaneous expression of p21 and mdm2 in breast carcinomas treated by adjuvant chemotherapy with antracyclin. Oncol Rep. 2000 May-Jun;7(3):675–680. doi: 10.3892/or.7.3.675. [DOI] [PubMed] [Google Scholar]
  17. McClelland R. A., Gee J. M., O'Sullivan L., Barnes D. M., Robertson J. F., Ellis I. O., Nicholson R. I. p21(WAF1) expression and endocrine response in breast cancer. J Pathol. 1999 Jun;188(2):126–132. doi: 10.1002/(SICI)1096-9896(199906)188:2<126::AID-PATH340>3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]
  18. Michalides R. J. Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer. J Clin Pathol. 1999 Aug;52(8):555–568. doi: 10.1136/jcp.52.8.555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Michieli P., Li W., Lorenzi M. V., Miki T., Zakut R., Givol D., Pierce J. H. Inhibition of oncogene-mediated transformation by ectopic expression of p21Waf1 in NIH3T3 cells. Oncogene. 1996 Feb 15;12(4):775–784. [PubMed] [Google Scholar]
  20. Mitchell K. O., El-Deiry W. S. Overexpression of c-Myc inhibits p21WAF1/CIP1 expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells. Cell Growth Differ. 1999 Apr;10(4):223–230. [PubMed] [Google Scholar]
  21. Reed W., Flørems V. A., Holm R., Hannisdal E., Nesland J. M. Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients. Virchows Arch. 1999 Aug;435(2):116–124. doi: 10.1007/s004280050408. [DOI] [PubMed] [Google Scholar]
  22. Rey M. J., Fernández P. L., Jares P., Muñoz M., Nadal A., Peiró N., Nayach I., Mallofré C., Muntané J., Campo E. p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. J Pathol. 1998 Mar;184(3):265–271. doi: 10.1002/(SICI)1096-9896(199803)184:3<265::AID-PATH8>3.0.CO;2-8. [DOI] [PubMed] [Google Scholar]
  23. Sherr C. J. Cancer cell cycles. Science. 1996 Dec 6;274(5293):1672–1677. doi: 10.1126/science.274.5293.1672. [DOI] [PubMed] [Google Scholar]
  24. Somasundaram K., Zhang H., Zeng Y. X., Houvras Y., Peng Y., Zhang H., Wu G. S., Licht J. D., Weber B. L., El-Deiry W. S. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature. 1997 Sep 11;389(6647):187–190. doi: 10.1038/38291. [DOI] [PubMed] [Google Scholar]
  25. Steinman R. A., Hoffman B., Iro A., Guillouf C., Liebermann D. A., el-Houseini M. E. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene. 1994 Nov;9(11):3389–3396. [PubMed] [Google Scholar]
  26. Upadhyay S., Li G., Liu H., Chen Y. Q., Sarkar F. H., Kim H. R. bcl-2 suppresses expression of p21WAF1/CIP1 in breast epithelial cells. Cancer Res. 1995 Oct 15;55(20):4520–4524. [PubMed] [Google Scholar]
  27. Wakasugi E., Kobayashi T., Tamaki Y., Ito Y., Miyashiro I., Komoike Y., Takeda T., Shin E., Takatsuka Y., Kikkawa N. p21(Waf1/Cip1) and p53 protein expression in breast cancer. Am J Clin Pathol. 1997 Jun;107(6):684–691. doi: 10.1093/ajcp/107.6.684. [DOI] [PubMed] [Google Scholar]
  28. Xiong Y., Hannon G. J., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 1993 Dec 16;366(6456):701–704. doi: 10.1038/366701a0. [DOI] [PubMed] [Google Scholar]
  29. el-Deiry W. S., Harper J. W., O'Connor P. M., Velculescu V. E., Canman C. E., Jackman J., Pietenpol J. A., Burrell M., Hill D. E., Wang Y. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994 Mar 1;54(5):1169–1174. [PubMed] [Google Scholar]
  30. el-Deiry W. S., Tokino T., Velculescu V. E., Levy D. B., Parsons R., Trent J. M., Lin D., Mercer W. E., Kinzler K. W., Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993 Nov 19;75(4):817–825. doi: 10.1016/0092-8674(93)90500-p. [DOI] [PubMed] [Google Scholar]
  31. el-Deiry W. S., Tokino T., Waldman T., Oliner J. D., Velculescu V. E., Burrell M., Hill D. E., Healy E., Rees J. L., Hamilton S. R. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res. 1995 Jul 1;55(13):2910–2919. [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES